Tasks and responsibilities
We have a position for a project manager for the Hemato-Oncology Precision Medicine program, who will be the key figure in setting up the logistics of the international Molecular Tumor Board. You will be part of a team at the Princess Maxima Center together with the project coordinator (MD), oncogenomics expert (PhD), research technicians and bioinformatician. You will collaborate with the Trial and Data Center to set up a database to register patients and document clinical and molecular information. You will take a leading role in setting up the infrastructure for the European partners and to develop uniform target prioritization and advice for early clinical trials. You will get hands-on experience in the interpretation of molecular profiles and drug sensitivity data to prioritize actionable events.

We are looking for a pro-active post-doc with a PhD in the field of biomedical sciences and an excellent understanding of oncogenetics and genomic profiling. Experience with the generation and analysis of next-generation sequencing data, informed consent and ethical procedures is an advantage. Our candidate has good coordinating skills and fosters effective communication with the different disciplines needed to bring this project to a success. Our group welcomes a candidate who is eager to learn, is a team player and who has a good command of the Dutch and English language.

Fixed-term contract: 1 year.

You will initially be appointed for a period of 1 year, with a possible extension to 2 or more years (full-time). Your gross monthly salary will depend on experience and background, starting in scale 55 with 8.33% gross monthly salary holiday allowance and 8.33 % end-of-year bonus. The Princess Máxima Center operates according to the collective labor agreement ‘cao algemene ziekenhuizen’.

Princess Máxima Center for Pediatric Oncology

The Princess Máxima Center for Pediatric Oncology is a new research hospital, which concentrates healthcare, research, and education with regard to cancer in children in a single location in the Netherlands. The institute aims to provide the highest level of care for all children with cancer and has the ambition to cure all children of cancer and to significantly reduce unwanted side effects. The center brings together the best possible care and scientific research, creating a unique interdisciplinary institute for pediatric oncology in Europe.

Research group 'Den Boer'

The research group of Prof. Monique den Boer (20fte) has a 25-year track record in preclinical and translational research in childhood leukemia. We have expertise in so-called pathobiological studies addressing which genetic lesions characterize the patients’ leukemia and how these lesions affect the behavior of leukemic cells and the interaction with the bone marrow microenvironment. This knowledge is needed to develop strategies that kill leukemic cells more specifically, also given the emerging role for precision medicines and immunotherapeutic strategies. Over the past two years, we have piloted genomic profiling to prioritize precision medicines for children with relapsed hematological malignancies without standard treatment options. A recently awarded Oncode Proof-of-Concept grant gives us the opportunity to scale up this translational project to an international Molecular and Clinical Tumor Board. This international platform will bring together European experts and combine the interpretation of molecular profiles and the trial eligibility of patients, to improve clinical outcome and reduce side-effects for children with hematological malignancies.